Beruflich Dokumente
Kultur Dokumente
com 1
Please Review Disclosures on Page 29 of this Research Report
INITIATION REPORT
Biotechnology ,QGXVWU\November 27, 2012
KEITH A. MARKEY, PH.D., M.B.A.
212-514-7914
KMARKEY@GRIFFINSECURITIES.COM
ORAGENI CS, I NC. (OT CBB: OGEN)
I NTRE XON COL L ABORA TI ON ADDS SI GNI F I CANT VALUE
x Oragenics & Intrexon are targeting the multi-billion dollar antibiotics mar ket. The collaboration grants
Oragenics exclusive access to Intrexon`s advanced industrial engineering platform for lantibiotics, a family of
more than 50 naturally occurring antibiotics.
o The lead drug candidate is Oragenics`s mutacin 1140 (MU1140), which has a broad spectrum of
activity against such virulent bacteria as multi-drug resistant Staphylococcus aureus (MRSA),
Mycobacterium tuberculosis, and Clostridium difficile.
o Intrexon, the leading synthetic biology company, will contribute advanced t ransgene and cellular
engineering expertise to enable lantibiotic production. Success with MU1140 will position the
collaborators to produce lantibiotics as active pharmaceutical ingredients for a wide range of antibiotic drug
products.
x Recent $13 million fi nancing brings Fidel ity and Randal J. Ki r k as investors. We expect current cash to last
until mid-2014 supporting the Intrexon lantibiotics collaboration and growth of the oral probiotics products.
x Probiotics sales are poised for substantial growth. Oragenics has proprietary products based on beneficial
bacteria that protect against tooth decay and gum disease. Two clinical trials should soon show the Evora
line
favorably alters the bacterial composition of the human mouth, leading to better health, improved breath, and
whiter teeth. Meanwhile, EvoraPets should increase its penetration of the $47 billion pet market.
We are initiating coverage with a BUY recommendation and $5.00 price target.
Oragenics, Inc. (OTCBB:OGEN) is a biotechnology
company with commercial probiotic products for
humans and pets and an R&D pipeline focused on
antibiotics through a collaboration with Intrexon
Corporation. The four probiotic products contain the
first comprehensive patented probiotic technology for
oral care, ProBiora3
ProDentis
Periobalance
chewing gum. One or both products are sold in North America, parts of Europe,
and Japan along with health-related offerings that do not include probiotics.
EvoraPets is also sold as Teddy's Pride